The role of PUVA in the treatment of psoriasis: Photobiology issues related to skin cancer incidence

被引：39

作者：

Gasparro F.P. ^{[1
,2
]}

机构：

[1] Photobiology Laboratory, Dept. Dermatol. and Cutaneous Biol., Thomas Jefferson University, Philadelphia, PA

[2] Photobiology Laboratory, Dept. Dermatol. and Cutaneous Biol., Thomas Jefferson University, Philadelphia

来源：

American Journal of Clinical Dermatology | 2000年 / 1卷 / 6期

关键词：

Squamous Cell Carcinoma; Psoriasis; Skin Cancer; Vitiligo; Psoralen;

D O I：

10.2165/00128071-200001060-00002

中图分类号：

学科分类号：

摘要：

Photochemotherapy with methoxsalen (8-methoxypsoralen) and long wavelength ultraviolet (UV) radiation (referred to as 'PUVA' for psoralen plus UVA) is commonly used to treat psoriasis and vitiligo. These vastly different diseases respond to the therapy by different mechanisms even though the immediate effects of the therapy - the photomodification of cellular biomolecules - is the same for each. Because psoriasis is not cured by PUVA, patients receive many treatments over their lifetime and have a significantly increased risk for the development of skin cancers (primarily squamous cell carcinomas). In this article the basic aspects of psoralen photobiology are reviewed briefly. Several recent studies describing the incidence of skin cancer in UVA treated psoriasis cohorts are comparatively reviewed. In addition the impact of the analysis of mutations in the tumor suppressor gene, p53, are summarized. An unexpected mutation spectrum (very few PUVA type T→A transversions and frequent UVB solar signature C→T transitions) suggest that effects other than direct DNA photoadduct formation may be at play. These analyses suggest that it may be possible to improve the therapeutic efficacy of PUVA by a careful evaluation of the mode of delivery. In this review the science behind PUVA is summarized. In addition, the incidence of skin cancer as a long term consequence of repeated treatments is surveyed. To relate clinical observations to molelcular events, the nature of p53 mutations found in skin cancers from psoriasis patients is also analyzed. Finally some suggestions for improving the delivery of PUVA therapy are presented.

引用

页码：337 / 348

页数：11

共 68 条

[1]

Fitzpatrick T.B., Pathank M.A., Research and development of oral psoralen and longwave radiation photochemotherapy: 2000 B.C.-1982 A.D., Natl Cancer Inst Monogr, 66, pp. 3-11, (1984)

[2]

El Mofty A.M., A preliminary clinical report on the treatment of leukoderma with Ammi majus linn, JR Egypt Med Assn, 31, pp. 651-665, (1948)

[3]

Bethea D., Fullmer B., Syed S., Et al., Psoralen photobiology and photochemotherapy: 50 years of science and medicine, J Dermatol Sci, 19, pp. 78-88, (1999)

[4]

Peritz A.E., Gasparro F.P., Psoriasis, PUVA and skin cancer - Molecular epidemiology: The curious question of T→A transversions, J Investig Dermatol Symp Proc, 4, pp. 11-16, (1999)

[5]

Morison W.L., Baughman S.D., Day R.M., Et al., Consensus workshop on the toxic effects of long-term PUVA therapy, Arch Dermatol, 134, pp. 595-598, (1998)

[6]

Halpern S.M., Guidelines for topical PUVA: A report of a workshop of the British photodermatology group, Br J Dermatol, 142, pp. 22-31, (2000)

[7]

Koo J.Y., Current consensus and update on psoriasis therapy: A perspective from the US, J Dermatol, 26, pp. 723-733, (1999)

[8]

Karasek M.A., Progress in our understanding of the biology of psoriasis, Cutis, 64, pp. 319-322, (1999)

[9]

Nickoloff B.J., The immunologic and genetic basis of psoriasis, Arch Dermatol, 133, pp. 1104-1110, (1999)

[10]

Honigsmann H., Fitzpatrick T.B., Pathak M.A., Et al., Oral photochemotherapy with psoralen and UVA (PUVA): Principles and practice, Dermatology in General Medicine, pp. 1728-1754, (1987)

← 1 2 3 4 5 6 7 →